Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Heidi T. Zafra MD
Associate Professor
Department of Pediatrics
Division of Allergy
Associate Professor in Pediatrics and Medicine
Division of Allergy/ Clinical Immunology
Asthma Allergy Section Chief; Children’s Wisconsin (CW)

OFFICE ADDRESS:
Children's Hosp Ofc Bldg
9000 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
06/1982 - 03/1986 BS, University of the Philippines, Philippines
06/1986 - 03/1990 MD, University of the East, Philippines

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
05/1990 - 04/1991 Post Graduate Rotating Internship, St. Luke’s Medical Center, Manila, Philippines
06/1993 - 06/1996 Resident, Pediatrics, North Shore University Hospital, Manhasset, NY
07/1996 - 06/1998 Fellowship, Allergy/Immunology, Cornell University Medical Center, New York, NY

FACULTY APPOINTMENTS:
07/1996 - 06/1998 Clinical Instructor, Division of Allergy, Immunology and Pulmonology, Cornell University Medical College, New York, NY
07/1998 - 06/2001 Assistant Professor, Pediatrics, Allergy, MCP-Hahnemann School of Medicine, Philadelphia, PA 19134
07/2001 - 06/2015 Assistant Professor, Pediatrics and Medicine, Allergy/ Immunology, Medical College of Wisconsin, 9000 W. Wisconsin Ave., Suite 440, Milwaukee, WI 53226
07/2015 - Present Associate Professor, Pediatrics and Medicine, Allergy/ Immunology, Medical College of WI, 9000 W. Wisconsin Ave, Suite 440, Milwaukee, WI 53226

ADMINISTRATIVE APPOINTMENTS:
07/1999 - 06/2001 Director, Subsection of Allergy, Section of Pulmonology and Allergy, St. Christopher’s Hospital for Children, Philadelphia, PA
07/2001 - 06/2003 Director, St. Christopher’s Hospital for Children, The Asthma Center, Philadelphia, PA
01/2013 - 09/2016 Director of Immunotherapy, Pediatrics, Allergy/ Immunology, Children's Hospital of Wisconsin, 9000 W. Wisconsin Ave, Suite 440, Milwaukee, WI 53226

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
07/1999 - 06/2001 Course Director, Pediatrics, Pediatric Allergy, MCP-Hahnemann School of Medicine, Philadelphia, PA
06/2002 - 06/2007 Director of Allergy/ Immunology Resident Education (Pediatrics), Medical College of Wisconsin, Milwaukee, WI
06/2007 - 09/2016 Associate Fellowship Program Director, Pediatrics, Allergy/ Immunology, Medical College of Wisconsin, 9000 W. Wisconsin Ave, Suite 440, Milwaukee, WI 53226
10/2008 - 09/2016 CME Activity Director, Pediatrics, Division of Allergy/ Immunology, Medical College of Wisconsin, 9000 W. Wisconsin Ave, Suite 440, Milwaukee, WI 53226
10/2013 - 04/2018 Director, Annual Program Fellowship Evaluation Committee, Pediatrics, Allergy/ Immunology, Medical College of WI, Suite 440, Suite 440, Milwaukee, WI 53226
09/2016 - 04/2018 Fellowship Program Director, Pediatrics, Allergy/ Immunology, Medical College of WI, 9000 W. Wisconsin Ave., Suite 440, Milwaukee, WI 53226

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
02/2021 - Present Asthma Allergy Section Chief, Pediatrics, Allergy/ Immunology, Children's Wisconsin, 9000 W. Wisconsin Ave, Suite 440, Milwaukee, WI 53226

RESEARCH ADMINISTRATIVE APPOINTMENTS:
02/2021 - Present Director, Clinical Research Trials, Pediatrics, Allergy/ Immunology, Medical College of WI, 9000 W. Wisconsin Ave., Suite 440, Milwaukee, WI 53226

HOSPITAL STAFF PRIVILEGES:
07/1998 - 06/2001 St. Christopher’s Hospital for Children, Erie Avenue at Front Street, Philadelphia, PA 19134
07/2001 - Present Clement J. Zablocki VA Medical Center, 5000 W. National Ave., Milwaukee, WI 53295
07/2001 - Present Children’s Hospital of Wisconsin, 9000 W. Wisconsin Avenue, Milwaukee, WI 53226
07/2001 - Present Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
American Board of Pediatrics
10/1996
10/2010
American Board of Allergy and Immunology
09/2001
12/2021
 
Licensure
Number Issue DateExpiration
New Jersey License (inactive)
MA066232
07/01/1999
06/30/2001
Pennsylvania License (inactive)
MD064828L
11/01/2000
12/31/2002
Wisconsin License
43348-020
05/31/2001
10/31/2021
 

AWARDS AND HONORS:
05/2001 “Top Docs for Kids” for Allergy , Philadelphia Magazine
02/2005 - 2006 "Top Physicians 2004-2005", Consumer's Research Council of America
2010 - 2014 Best Doctors in America
2012 - 2020 Best Doctors, M Magazine
2016 - 2020 Top Doctors, Castle Conolly, Milwaukee Magazine

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
07/1993 - Present American Academy of Pediatrics (Fellow)
07/1996 - Present American College of Allergy, Asthma and Immunology (Fellow)
07/1996 - Present American Academy of Allergy, Asthma and Immunology (Fellow)
07/1998 - 07/2001 Philadelphia Allergy Society (Member)
07/2001 - Present Wisconsin Allergy Society (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
02/2021 - Present Reviewer, Annals of Allergy, Asthma and Immunology
Ad-Hoc Reviewer
09/2018 - Present Grant Reviewer, Clinical and Translational Science Institute (CTSI) of Southeastern Wisconsin Pilot Award Program
02/2021 - Present Reviewer, American College of Allergy, Asthma and Immunology (ACAAI) Fellow in Training Board Review Case Vignettes

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
06/2013 - 09/2016 Member, Leadership Board, American Lung Association (ALA), Wisconsin Chapter

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
03/2003 - Present Member, Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (ADDA) Interest Section, American Academy of Allergy, Asthma and Immunology
03/2003 - 2013 Member, Rhinitis Committee, American Academy of Allergy, Asthma and Immunology
01/2008 - 2016 Member, Atopic Dermatitis/ Eczema Committee, American Academy of Allergy, Asthma and Immunology
09/2016 - 04/2018 Member, Program Director's Assembly, American Academy of Allergy, Asthma and Immunology
02/2018 - Present Member, Health Outcomes, Education, Quality and Delivery Interest Section, American Academy of Allergy, Asthma and Immunology
11/2019 - Present Member, Biologics and Pharmacology Committee, Thymic Stromal Lymphopoietin (TSLP) Subcommittee, American College of Allergy, Asthma and Immunology
11/2019 - Present Member, Immunotherapy and Diagnostics Committee, American College of Allergy, Asthma and Immunology
08/2020 - Present Invited Member, Advisory Voard, Takeda Pharmaceuticals Advisory Board
03/2021 - Present Invited Member, Advisory Board, Biocryst Pharmaceuticals

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
An open-label study to evaluate the long-term safety of daily oral BCX7353 with Type I and II hereditary angioedema
Source:
Biocryst Pharmaceuticals
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
11/2019 - Present
Direct Funds:
$23,049 (per patient)
 
Title:
A 5-year Longitudinal Observational Study of PatientsUndergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
Source:
Target Pharma Solutions
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
10/2020 - Present
Direct Funds:
$1,930 (per patient)
 
Title:
A Multicentre, Randomized, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (NATRON)
Source:
AstraZeneca
Role:
Prinicpal Investigator
PI:
Heidi Zafra MD
Dates:
12/2020 - Present
Direct Funds:
$98,722 (per patient)
 
Non-Peer Review
Title:
Jordan Fink Lectureship (#9212007)
Source:
Children's Hospital Foundation
Role:
Activity Director
Dates:
2010 - Present
Direct Funds:
$30,000
 
Pending
Peer Review
Title:
A Randomized, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium, and Formoterl Fumarate Metered Dose Inhalaer (MDI) Relative to Budesonide and Formoterol Furmarate MDI and Symbicort Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
Source:
AstraZeneca
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
2021 - Present
 
Title:
SWIFT-2: A 52-week, randomised, double blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe incontrolled asthma with an eosinophilic phenotype
Source:
Glaxo Smith Kline (GSK)
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
2021 - Present
 
Prior
Peer Review
Title:
D3250C00018: A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Pluas Long-acting B2 agonist in Patients with Uncontrolled Asthma (CALIMA)
Source:
AstraZeneca
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
12/2013 - 09/2016
Direct Funds:
$60,746
 
Title:
A Phase III, Randomized, Double-Blind, Placebo-controlled study to assess the efficacy, safety and tolerability of Lebrakizumab in adolescents with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication
Source:
Roche/ Genentech
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
02/2014 - 08/2016
 
Title:
HELP StudyTM: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Eficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema
Source:
Dyax Corp
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
11/2015 - 04/2018
Direct Funds:
$67,392
 
Title:
A Multicentre, randomized, Parallel Group, Phase 3 Safety Extension to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting B2 Agonist (BORA)
Source:
AstraZeneca
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
01/2016 - 08/2018
Direct Funds:
$28,328
 
Title:
A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma
Source:
Merck
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
09/2016 - 07/2017
Direct Funds:
$4,038
 
Title:
Dyax-2930-04 HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema
Source:
Dyax Corp
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
10/2016 - 03/2020
Direct Funds:
$67,932
 
Title:
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Safety and Eficacy of Benralizumab 30mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment (ANDHI)
Source:
AstraZeneca
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
10/2017 - 06/2019
 
Non-Peer Review
Title:
Pediatric Asthma Adherence Questionnaire Study
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
03/2011 - 11/2016
 
Title:
Impact of Food Allergies on Nutrition
Role:
Co-Investigator
PI:
Praveen Goday MD
Dates:
03/2011 - 04/2016
 
Title:
Evaluation of At-Home Egg in Baked Product Oral Food Challenge
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
02/2013 - 01/2015
 
Title:
Systemic Reactions to Immunotherapy: A Retrospective Review of Our Practice
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
09/2014 - 02/2015
 
Title:
Utility of Egg Component Resolved Diagnostic Testing in Predicting the Necessity for In-Office Food Challenges
Source:
Thermofisher
Role:
Principal Investigator
PI:
Heidi Zafra MD
Dates:
11/2015 - 2017
Direct Funds:
$20,000
 
Title:
The Use of a Health Decision Tree Support Program for Epinephrine Autoinjector (EAI) Administration Training of Adolescents
Role:
Co-Investigator
PI:
Joel Gallagher MD
Dates:
02/2016 - 06/2017
 
Title:
Improving Medication Adherence for Pediatric Asthma Patients Using Innovative Smartphone Apps, UWM Grant Proposal
Role:
Faculty Mentor
Dates:
03/2017 - 12/2017
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Zafra H, A New Treatment for Asthma, Anti-IgE, Grand Rounds, St. Christopher’s Hospital for Children, Philadelphia, PA, 08/21/1998
Zafra H, Anaphylaxis Urticaria and Angioedema, MCP-Hahnemann School of Medicine, Philadelphia, PA, 10/01/1998
Zafra H, EIB: Diagnosis and Management, Dept of Sports Medicine, Medical College of WI, Milwaukee, WI, 06/14/2011
Zafra H, Understanding the New Asthma Guidelines, Southwest Pediatrics, New Berlin, WI, 04/16/2012
Zafra H, Improving Asthma Outcomes, Children's Health Alliance Office, Milwaukee, WI, 07/16/2015
Zafra H, Personalizing Asthma Control in Clinical Practice, Children's Specialty Group Lectures, Milwaukee, WI, 07/2015 - 10/2015
 
Regional
Zafra H, Allergy Case Discussions, The Forty Eighth Annual St. Christopher’s Hospital For Children Update Pediatrics, Philadelphia, PA, 06/09/1999
Zafra H, New Options for Asthma Management, Forty-Ninth Annual St. Christopher’s Hospital For Children Update Pediatrics, Philadelphia, PA, 05/23/2000
Zafra H, The Dual Components of Asthma and the Benefits of Combination Therapy, Easton Hospital First Annual Pediatric Seminar, Easton, PA, 11/29/2000
Zafra H, New Therapies for Asthma Management, Reading Hospital Pediatric Seminar, Reading, PA, 01/05/2001
Zafra H, Current Concepts in Pediatric Respiratory Disease, Capital Health Systems, Trenton, NJ, 06/08/2001
Understanding the New Asthma Guidelines, American Academy of Pediatrics, Wisconsin Chapter, Milwaukee, WI, 04/19/2008
Zafra H, Asthma Overview and Pathophysiology, American Lung Association (ALA) Asthma Educators Program, Asthma Educator Institute, Wheaton Health, Milwaukee, WI, 11/09/2012 - 12/09/2015
Zafra H, Improving Asthma Outcomes, American Lung Association Lung Expo, Milwaukee, WI, 07/16/2015
 
National
Kelly B, Bauer CS, Nugent ML, Kelly KJ, Gimenez L, Zafra H., The Pediatric Asthma Adherence Test (PAAT): A Survey for Pediatric Patient Propensity to Adhere to Controller Medications (Oral Presentation), Presentation at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Atlanta, GA, 11/06/2014
Gobin K*, Sheppard K, Chiu A, Zafra H, Quality Improvement Survey Assessing Immunotherapy Efficacy and Barriers in an Outpatient Setting (Oral Presentation), Presentation at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Boston, MA, 10/28/2018
 
International
Zafra H, Practical and Effective Asthma Care, Philippine Medical Society, Philadelphia, PA, 06/11/1999
 

PEER REVIEWED WORKSHOPS/PRESENTATIONS:
Local
Bauer CS, Chiu AM, Zafra H, Gimenez LM, Nugent ML, Simpson PM, Vasudev M, . "Why Should I Rotate in Allergy and Clinical Immunology During Medical School or Residency?, Department of Pediatrics, The Joint Fellowship Curriculum (JFC) Committee Research Day, Milwaukee, WI, 04/2013
 
Regional
Sova C, Feuling M, Baumier M, Gleason L, Tam J, Tam J, Zafra H., Goday P, Changes in Calcium Intake in Children with Multiple Food Allergies that Received Medical Nutrition Therapy, Wisconsin Academy of Nutrition and Dietetics Annual Conference, Milwaukee, WI, 04/18/2013
 
National
Healy CT*, Zafra H, Zacharisen MC, Thyroid goiter masquerading as asthma, Abstracts: Poster Sessions, American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, San Antonio, TX, 11/10/2002 - 11/15/2002
Duke RL*, Kidder T, Zafra H, Idiopathic anaphylaxis associated with sialoadenitis, Annual meeting of the American Academy of Otolaryngic Allergy Foundation (AAOAF), Orlando, FL, 09/2003
Buelow B, Lee C, Zafra H, Dasgupta M, Hoffmann R, Vasudev M, The Majority of Egg Allergic Patients Tolerate Egg Baked in Product at Oral Food Challenge, Abstracts: Poster Sessions, American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Baltimore, MD, 11/07/2003
Vasudev M, Martinez A, Levy MB, Zafra H, Severe Cow’s Milk Protein Sensitivity in a Child with C. Difficile Colitis, Abstracts: Poster Sessions, American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Philadelphia, PA, 11/2006
Buelow B, Kelly B, Zafra H, Kelly KJ, The value of BAL in Acute Eosinophilic Pneumonia of Allen, Abstracts: Poster Sessions, American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Baltimore, MD, 11/07/2013 - 11/11/2013
Tallar M , Chen W, Gallagher M, Gedeit R, and Zafra H, Compartment Syndrome Requiring Fasciotomy in a Patient with HAE Type 1: a Case Report, Abstracts: Poster Sessions, American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Atlanta, GA, 11/06/2015 - 11/10/2015
Buelow B, Zafra H, The Diagnosis is in the History: A Case of DRESS in a Pediatric Patient, American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Atlanta, GA, 11/06/2015 - 11/10/2015
Kelly B, Bauer CS, Nugent ML, Simpson PM, Kelly KJ, Gimenez LM, Zafra H, The Pediatric Asthma Adherence Test (PAAT): A Survey for Pediatric Patient Propensity to Adhere to Controller Medications, Abstract and Oral Presentation at American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Atlanta, GA, 11/06/2015 - 11/10/2015
Peloza D, Gimenez L, Crandall L, Nugent M, Simpson P, Zafra H, Pediatric Asthma Adherence Test, Abstracts: Poster Sessions, American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, San Francisco, CA, 11/10/2016 - 11/14/2016
Gobin, K, Sheppard K, Chiu A, Zafra H, Quality Improvement Survey Assessing Immunotherapy Efficacy and Barriers in an Outpatient Setting, Abstract and Oral Presentation, American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Boston, MA, 10/26/2017 - 10/30/2017
Bashir M, Zafra H, Sebelipase Desensitization: A Case Report, Poster Sessions, American Academy of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, Orlando, FL, 03/02/2018 - 03/05/2018
Sexton D, Brown N, Lumry W, Gower G, Hao J, Lu P, Zafra H, Lanadelumab And Cardiovascular Risk: Findings From The Phase 3 HELP Study, Abstracts: Poster Sessions, American Academy of Allergy, Asthma and Immunology (AAAAI) Scientific Meeting, San Francisco, CA, 02/22/2019 - 02/25/2019
 

COMMITTEE SERVICE:
Medical College of Wisconsin
06/2007 - 2010 Member, Library Committee, Medical College of Wisconsin
10/2009 - 2010 Member, Library White Paper Subgroup, Medical College of Wisconsin
01/2010 Member, Internal Review Committee, Pediatric Endocrinology Fellowship Program, Medical College of Wisconsin
11/2011 - Present Member, Fellowship Work Group, Allergy/ Immunology, Pediatrics, Medical College of WI
2012 - Present Member, Intern Selection Committee, Pediatrics, Medical College of WI
04/2013 - 06/2013 Member, ERVU Education Advisory Committee, Pediatrics, Medical College of WI
08/2013 - 07/2016 Member, Faculty Council, Pediatrics, Medical College of WI
11/2020 - Present Member, Justice, Equity, Diversity and Inclusion, Workforce Subcommittee, Pediatrics, Medical College of WI
 
Hospital
03/2011 - 04/2012 Member, CSG Quality Committee, Pay for Performance Subcommittee, Children's Wisconsin
03/2012 - 07/2012 Member, Vaccine Clinic Implementation Planning, Children's Wisconsin
11/2014 - 06/2020 Member, Emergency Preparedness Committee, Allergy/ Immunology, Pediatrics, Children's WI
02/2018 - Present Member, Pharmacy and Therapeutics Committee, Pediatrics, Children's Wisconsin
04/2019 - 2020 Member, Translational / Clinical Research Advisory Committee, Pediatrics, Children's Wisconsin
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Medical Student Education
09/2004 Immunology Review
11/18/2009 - 2014 M2 Clinical Exam and Reasoning Course (CER) Preceptor, Teach Physical Exam findings (4 hours/ year)
01/2011 M1 Cardivascular/ Respiratory/ Renal (CVRR) Module Moderator
07/2011 - Present Apprenticeship in Medicine (AIM), for undergraduate/ high school students
07/2012 - 06/2013 Ambulatory Immersion Rotation
01/2013 - 05/2013 M1 Clinical Apprenticeship Course
02/2014 M2 Bench-to-Bedside ENT clinical skills workshop
03/2021 - Present ReasearchOpportunity for Academic Development in Science (for undergraduate/ high school students)
 
Resident and Fellow Education
2001 - 2008 Ace the Boards, Allergy/ Immunology Review Course for Pediatric Board Examinations
2007 - 2010 Vasculitis/ Rheumatology, Allergy/ Immunology Mini-Lectures
2007 - 2009 Insect Allergy, Allergy/ Immunology Mini-Lectures
2007 - 2015 Allergic Diseases in Pregnancy, Allergy/ Immunology Mini-Lectures
2009 - Present Allergy/ Immunology Journal Club
2011 - 2019 Immunomodulators, Allergy/ Immunology Mini-Lectures
06/2013 Annual Procedure Workshop for Interns
06/2013 - 06/2016 MCWAH House Staff Orientation
08/2014 Noon Conference, Pediatrics
 
Continuing Medical Education
11/17/2005 Gender Related Differences in Allergy/ Asthma, Allergy/ Immunology Grand Rounds
09/2006 - 05/30/2008 Complementary and Alternative Medicine, Allergy/ Immunology Grand Grounds
2007 - 2013 Aeroallergens, Allergy/ Immunology Grand Rounds
2014 - 2017 Aeroallergens and Immunotherapy, Allergy/ Immunology Grand Rounds
2018 - 2020 Hereditary Angioedema, Allergy/ Immunology Grand Rounds
02/21/2020 - Present Biologics in Asthma, Allergy/ Immunology Grand Rounds
 

EXTRAMURAL TEACHING:
Community/Lay Public
11/2004 Schoeder YMCA, Milwaukee, WI, Exercise and Asthma (Community Education Class)
06/2005 Women's Wellness Wednesday, Wisconsin Athletic Club, Allergic Rhinitis and Sinusitis (Community Education Class)
07/2010 Community Memorial Hospital, Menomonee Falls, WI, Asthma and Allergies (Community Education Class)
 
Nursing Student Education
08/05/2009 Children's Wisconsin, Insect Allergy Lecture for Nursing Staff Teaching lecture for the nurses and medical assistants of the Allergy Clinic
02/2012 - 02/2013 Children's Wisconsin, Nursing Staff Competency Training on Immunotherapy
 

PROGRAMMATIC DEVELOPMENTS:
Educational Programs
Fellow
07/2008 - 09/2016 Associate Program Director, organized the educational, clinical and research activities from a 2yr to 3yr program
09/2016 - 04/2018 Program Director, Revision of Allergy/ Immunology Fellowship Program Curriculum
Faculty
07/2008 - 09/2016 CME Activity Director, coordinated and completed CME Program Compliance requirements, invited speakers
2010 - Present Jordan Fink Lecture Series, organizer and coordinator (invite a nationally recognized speaker annually)
 
 
Clinical Programs
11/2010 - 12/2011 Launched a Children's WI/ Froedtert Hospital/ Community Memorial Clinic (Developed an EMR system specifically tailored for Allergy/ Immunology
01/2012 - 2012 Revision Allergen Immunotherapy Safety Protocols
04/2012 - 2012 Development of Omalizumab Guidelines
07/2012 - 2012 Development of Aspirin Desensitization Guidelines
12/2012 - 2012 Development of Baked Egg Food Challenge Guidelines
04/2013 - 2013 Revision the Asthma/Allergy Clinics Anaphylaxis Protocol
01/2014 - 2014 Improving Efficacy of Immunotherapy Prescriptions (Revision of Immunotherapy)
02/2014 - 2014 QI PRoject: Meta-analysis of anaphylaxis events in the Asthma/ Allergy Clinics
02/2016 - 2018 Development and Revision of the Immunotherapy Send Out Guidelines
11/2017 - 2017 QI Project: Quality Improvement Survey Assessing Immunotherapy Efficacy and Barriers in an Outpatient Setting (CW Value Champions Project)
03/2018 - 2018 QI Project: Quality Improvement PRoject on Fellow Proficiency in Writing Allergen Immunotherapy Prescriptions
 
Community Programs
2009 - 2013 Nationwide Asthma Screening Program, sponsored by the American College of Allergy, Asthma and Immunology (ACAAI)
 

COMMUNITY SERVICE ACTIVITIES:
06/2013 American Lung Association Active with Asthma Day Camp (Volunteer Staff), Bayview High School, Milwaukee, WI.
10/2013 American Lung Association Fight for Air Walk (Guest Speaker and Participant), Milwaukee, WI.
05/2015 05/2015 American Lung Association (ALA) Lung Expo Planning Committee Member and volunteer, Italian Community Center, Milwaukee, WI.
2018 - Present University School of Milwaukee (USM) parent volunteer for high school tennis, ski team and lacrosse
2018 - Present Milwaukee Folk Fair volunteer, Philippine booth
 

GLOBAL HEALTH ACTIVITIES:
2001 - Present Member of the University of the Philippines Alumni Association (UPAA)
2001 - Present Member of the Philippine Medical Association-WI chapter
09/2018 - Present Participates as a clinician in the Philippine Center Free Clinic, one half day per month.
 

CLINICAL INVESTIGATION/CLINICAL STUDIES:
07/1996 - 06/1997 A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Anti-IgE Recombinant Humanized Monoclonal Antibody (rhuMAb-E25) in Patients with Moderate to Severe Allergic Asthma. Sub-Investigator. (Genentech, Inc.)
01/1997 - 06/1998 Rhinoconjunctivitis Quality of Life Questionnaire among Hispanics MAPI Research Institute
06/1997 - 06/1998 A Randomized, Open Label, Cross-Over Study Comparing Parent-Guardian Preference for Montelukast Sodium Tablets or Cromolyn Aerosol (MDI) Treatment in their Children ages 6 to 11 with Chronic Asthma. Sub-Investigator. (Merck)
01/2001 - 06/2001 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled, 12-Week study of Fluticasone mcg BID delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma age 24 Months to 47 months, 6 Months to 23 Months. Sub-Investigator. (GlaxoWellcome Inc.)
06/2002 - 06/2003 Glaxo Smith Kline, Randomized, Double-Blind, 12-Week Trial Evaluating the Safety of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg BID Versus Fluticasone Propionate DISKUS 100 mcg BID in Symptomatic Pediatric Subjects (4-11years) with asthma.
06/2002 - 06/2003 Novartis, A Randomized, Multicenter, Placebo-Controlled Parallel Group Study of Four Months Duration Per Patient To Evaluate the Safety and Efficacy of Treatment with 24g BID and 12g BID Formoterol, with Additional on-demand Formoterol Doses, Open in Adolescent and Adult Patients with Persistent Stable Asthma.
09/2002 - 08/2003 Genentech, Open-Label Extension Study II of Xolair(Omalizumab) in Moderate to Severe, Persistent Asthma Subjects Who Completed Study Q2143g (ALTO)
10/2002 - 09/2003 AstraZeneca, A Six-Month, Randomized, Open-Label Safety Study of Symbicort™ (160/4.5mcg) Compared to Pulmicort Turbuhaler® in Asthmatic Children Aged Six to Eleven Years – Sapling
10/2002 - 09/2003 AstraZeneca, A Twelve-Week, Randomized, Double-Blind, Double-Dummy Trial of Symbicort™ (40/4.5) versus its Mono-Products (budesonide and formoterol) in Asthmatic Children Aged Six to Fifteen Years – SEEDLING 40/4.5
02/2003 - 01/2004 Altana, 12 Weeks Treatment with 125g Roflumilast Versus 250g Roflumilast Versus Placebo in Patients with Asthma Protocol No. BY217/FK1 021.
06/2003 - 05/2004 Astra Zeneca, A Randomized, Partly Blinded, Multicenter, Parallel Study Comparing the Efficacy and Safety of PULMICORT RESPULES (budesonide inhalation suspension) at 0.5 mg QD, 1.0 mg QD, 1.0 mg BID, 2.0mg BID and PULMICORT TURBUHALER (budesonide) at 400 mcg BID in Adolescents (12 Years of Age and Older) and Adults with Moderate to Severe Asthma Protocol SD-004-0764.
03/2004 - 02/2005 Novartis, CIGE025AIA05 A 1 Year, Randomized, Double Blind, Parallel-Group, Placebo-Controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Omalizumab in Children (6 - <12 years) With Moderate-Severe, Persistent, Inadequately Controlled Allergic Asthma.
07/2004 - 06/2005 Protocol Q2948g An Epidemiologic Study of Xolair® (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma (EXCELS)
08/2004 - 07/2005 Protocol No. QAB149A2216 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Multiple Dose (7 days) Dose-Ranging Study, to assess the Efficacy and Safety of 4 Doses of QAB149 (50, 100, 200 & 400 µg) Delivered Via the MDDPI and 1 Dose of QAB149 (400 µg) Delivered Via a SDDPI in Adult and Adolescent Patients (12 -75 years) With Stable Persistent Asthma.
03/2005 - 08/2005 Pathogenesis of Immunological Diseases/Studies in Immune Regulation
06/2005 - 05/2006 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Multiple Dose (7 days) Dose-Ranging Study, to Assess the Efficacy and Safety of 4 Doses of QAB149 (50, 100, 200 & 400 µg) Delivered Via the MDDPI and 1 Dose of QAB149 (400µg) Delivered Via a SDDPI in Adult and Adolescent Patients (12 - 75 years) With Stable Persistent Asthma
09/2005 - 08/2006 A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Persistent Asthma, Who Have Either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly Genotype and are Treated With Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg or Salmeterol DISKUS 50 mcg BIDSeptember, 2005Pathogenesis of Immunological Diseases/Studies in Immune Regulation
10/2005 - 01/2006 SFA100314 A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects with Activity Induced Bronchospasm December, 2005 Severity Assessment and Treatment of Asthma
08/2006 - 12/2006 A Phase IV Trial Evaluating Health Related Quality of Life and Serious Bacterial Infections in Subjects with Primary Immunodeficiency Disorder (PIDD) Treated with Subcutaneous Immune Globulin Following Conversion from Intravenous Globulin
08/2006 - 12/2006 Determination of Minimum and Non-provoking Doses of Soy Protein in Soy Allergic Individuals
08/2007 - 12/2007 GrassMATAMPL301: Efficacy and Safety/Tolerability of Grass MATA MPL, a Randomized, Placebo-Controlled, Double-Blind Study
08/2007 - 12/2007 ProtocolQ3662g: A Phase IIIb Multicenter, Randomized, Double Blind, Placebo Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma Who are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonist


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Zafra H, Zacharisen M.C. Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, Volume 1, Number 2, 2002, pp. 143-156(14). doi.org/10.2174/1568014023355962
2. Healy, CT*, Zafra H and Zacharisen, M.C. What caused progressive wheezing and cough in this woman? Journal of Respiratory Diseases. 2003; 24(5):223-225. SCOPUS ID: 2-s2.0-0038242099 05/01/2003
3. Gimenez LM, Zafra H. Vocal cord dysfunction: an update. Ann Allergy Asthma Immunol. 2011 Apr;106(4):267-74; quiz 275. doi: 10.1016/j.anai.2010.09.004. PMID: 21457874.
4. Bauer CS*, Chiu AM, Zafra HT, Gimenez LM, Nugent ML, Simpson PM, Vasudev M. The value of an allergy and clinical immunology rotation at an academic tertiary medical center. Ann Allergy Asthma Immunol. 2013 Jun;110(6):468-469.e9. doi: 10.1016/j.anai.2013.04.003. Epub 2013 Apr 30. PMID: 23706721.
5. Sova C, Feuling MB, Baumler M, Gleason L, Tam JS*, Zafra H, Goday PS. Systematic review of nutrient intake and growth in children with multiple IgE-mediated food allergies. Nutr Clin Pract. 2013 Dec;28(6):669-75. doi: 10.1177/0884533613505870. Epub 2013 Oct 28. PMID: 24166727.
6. Zafra H, Chiu A. The changing face of allergy/immunology fellowship programs. Ann Allergy Asthma Immunol. 2013 Nov;111(5):313-5. doi: 10.1016/j.anai.2013.09.006. PMID: 24125132.
7. Sova C, Feuling MB, Baumler M, Gleason L, Tam JS*, Zafra H, Goday PS. Systematic review of nutrient intake and growth in children with multiple IgE-mediated food allergies. Nutr Clin Pract. 2013 Dec;28(6):669-75. doi: 10.1177/0884533613505870. Epub 2013 Oct 28. PMID: 24166727.
8. Buelow BJ*, Lee C, Zafra HT, Dasgupta M, Hoffmann RG, Vasudev M. Egg baked in product open oral food challenges are safe in selected egg-allergic patients. Allergy Rhinol (Providence). 2014 Jul;5(2):110-2. doi: 10.2500/ar.2014.5.0092. Epub 2014 Jul 15. PMID: 25198996; PMCID: PMC4124576.
9. Buelow BJ*, Kelly BT, Zafra HT, Kelly KJ. Absence of Peripheral Eosinophilia on Initial Clinical Presentation Does Not Rule Out the Diagnosis of Acute Eosinophilic Pneumonia. J Allergy Clin Immunol Pract. 2015 Jul-Aug;3(4):597-8. doi: 10.1016/j.jaip.2015.01.008. Epub 2015 Feb 12. PMID: 25683924.
10. Chen WL, Gallagher J*, Zafra H, Gedeit R. Hereditary angioedema presenting as compartment syndrome in a white girl. Ann Allergy Asthma Immunol. 2016 Sep;117(3):321-2. doi: 10.1016/j.anai.2016.06.021. Epub 2016 Jul 7. PMID: 27397069.
11. FitzGerald JM1, Bleecker ER2, Nair P3, Korn S4, Ohta K5, Lommatzsch M6, Ferguson GT7, Busse WW8, Barker P9, Sproule S9, Gilmartin G10, Werkström V11, Aurivillius M11, Goldman M9; CALIMA study investigators*. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. Epub 2016 Sep 5. *Dr Zafra is one of the CALIMA study investigators
12. Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M.* Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018 May;120(5):504-511.e4. doi: 10.1016/j.anai.2018.01.030. Epub 2018 Feb 1. PMID: 29409951 *Dr Zafra is one of the CALIMA study investigators
13. DuBuske L, Newbold P, Wu Y, Trudo F.* Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab. Allergy Asthma Proc. 2018 Sep 4;39(5):345-349. doi: 10.2500/aap.2018.39.4162. Epub 2018 Aug 4. *Dr Zafra is one of the CALIMA study investigators
14. Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG.*Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 Oct 18;52(4). pii: 1800936. doi: 10.1183/13993003.00936-2018. Print 2018 Oct. *Dr Zafra is one of the CALIMA study investigators
15. Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F.* Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23.PMID: 3080250 *Dr Zafra is one of the CALIMA study investigators
16. Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators**. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Erratum in: Lancet Respir Med. 2019 Jan;7(1):e1.PMID: 30416083 **Dr Zafra is one of the BORA study investigators
17. Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, Busse PJ, Anderson J, Magerl M, Martinez-Saguer I, Davis-Lorton M, Zanichelli A, Li HH, Craig T, Jacobs J, Johnston DT, Shapiro R, Yang WH, Lumry WR, Manning ME, Schwartz LB, Shennak M, Soteres D, Zaragoza-Urdaz RH, Gierer S, Smith AM, Tachdjian R, Wedner HJ, Hebert J, Rehman SM, Staubach P, Schranz J, Baptista J, Nothaft W, Maurer M; HELP Investigators***. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA. 2018 Nov 27;320(20):2108-2121. doi: 10.1001/jama.2018.16773. Erratum in: JAMA. 2019 Apr 23;321(16):1636. PMID: 30480729 ***Dr Zafra is one of the HELP study investigators
18. Riedl MA, Bernstein JA, Craig T, Banerji A, Magerl M, Cicardi M, Longhurst HJ, Shennak MM, Yang WH, Schranz J, Baptista J, Busse PJ. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP*** study extension. Clin Transl Allergy. 2017 Oct 6;7:36. doi: 10.1186/s13601-017-0172-9. eCollection 2017. ***Dr Zafra is one of the HELP study investigators
19. Riedl MA, Maurer M, Bernstein JA, Banerji A, Longhurst HJ, Li HH, Lu P, Hao J, Juethner S, Lumry WR, Hébert J, Ritchie B, Sussman G, Yang WH, Escuriola Ettingshausen C, Magerl M, Martinez-Saguer I, Maurer M, Staubach P, Zimmer S, Cicardi M, Perego F, Wu MA, Zanichelli A, Al-Ghazawi A, Shennak M, Zaragoza-Urdaz RH, Ghurye R, Longhurst HJ, Zinser E, Anderson J, Banerji A, Baptist AP, Bernstein JA, Boggs PB, Busse PJ, Christiansen S, Craig T, Davis-Lorton M, Gierer S, Gower RG, Harris D, Hong DI, Jacobs J, Johnston DT, Levitch ES, Li HH, Lockey RF, Lugar P, Lumry WR, Manning ME, McNeil DL, Melamed I, Mostofi T, Nickel T, Otto WR, Petrov AA, Poarch K, Radojicic C, Rehman SM, Riedl MA, Schwartz LB, Shapiro R, Sher E, Smith AM, Smith TD, Soteres D, Tachdjian R, Wedner HJ, Weinstein ME, Zafra H, Zuraw BL. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology 2020 PMID: 32452549 SCOPUS ID: 2-s2.0-85087498118 01/01/2020 ***Dr Zafra is one of the HELP study investigators
20. Lumry WR, Weller K, Magerl M, Banerji A, Longhurst HJ, Riedl MA, Lewis HB, Lu P, Devercelli G, Jain G, Maurer M; HELPStudy Investigators***. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy. 2020 Nov 30. doi: 10.1111/all.14680. Epub ahead of print. PMID: 33258114. ***Dr Zafra is one of the HELP study investigators
21. Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators****. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Erratum in: Lancet Respir Med. 2021 Jan 25; PMID: 33357499. ****Dr Zafra is one of the ANDHI study investigators
 
Abstracts
1. Bauer C.S.*, Chiu A.M., Zafra H, Gimenez L.M., Nugent M.L., Simpson P.M., Vasudev M. The Value of an Allergy-Immunology Rotation in an Academic Tertiary Medical Center for Medical Student and Residents. Ann Allergy 2011;107: A110.
2. Tallar M, Gimenez L, Zafra H, Chiu A. Systemic Reactions to Aeroallergen Immunotherapy: A Retrospective Review of Our Practice. Abstract only, Vol 137, issue 2, supplement, AB48, February 1, 2016. DOI: 10.1016/j.jaci.2015.12.157.
3. Peloza D, Gimenez L, Crandall L, Nugent M, Simpson P, Zafra H. P127 The pediatric asthma adherence test: a survey for pediatric patient adherence to controller medications, Annals of Allergy, Asthma & Immunology,Volume 117, Issue 5, Supplement, 2016, Page S58, ISSN 1081-1206; https://doi.org/10.1016/j.anai.2016.09.137.
4. Gobin, K*, Sheppard K, Chiu A, Zafra H. OR090 Quality improvement survey assessing immunotherapy efficacy and barriers in an outpatient setting, Annals of Allergy, Asthma & Immunology, Volume 119, Issue 5, Supplement, 2017, Page S13,ISSN 1081-1206, https://doi.org/10.1016/j.anai.2017.08.065.
5. Sexton D, Brown N, Lumry W, Gower G, Hao J, Lu P, Zafra H. Lanadelumab And Cardiovascular Risk: Findings From The Phase 3 HELP Study. Abstract only, Vol 143, Issue 2, Supplement, AB45, Feb 01, 2019. DOI:https://doi.org/10.1016/j.jaci.2018.12.138
 
Non-Peer Reviewed Educational Products
1. ZAFRA, H.T., Gimenez, L., Zacharisen, M.. FAQ's on Latex -related occupational asthma. American Latex Allergy Association Website. http://www.latexallergyresources.org/related/OccupationalAsthma.cfm
2. ZAFRA, H. Tips that may help asthma sufferers enjoy the outdoors during “pollen season.” Metroparent Magazine, April 2013.
 
Database, Video, or Other Research/Clinical Contributions
1. ZAFRA, H. “Allergies to Cold---Allergic Rhinitis and Cold Urticaria.” WTMJ-AM Radio Broadcast, December 5, 2013
2. ZAFRA, H. Seasonal allergies. WTMJ-TV (NBC 4) Live at Noon. March 16, 2017.
3. ZAFRA, H. How to help fall/ winter allergies. WTMJ-TV (NBC 4) Live at Noon. Sept 19. 2019.